IGC Pharma

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The firm's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The firm integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. The company is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.